Open beta · everything is free with an account while we build. Founding accounts get preferred pricing when paid plans arrive. Create yours →
SK

SOPHIE KHANAHMADI

LMH STRATEGIC SOLUTIONS · Washington, DC
Registered · LDAActive

At a glance

Works on
Professional highlights appear here once this profile is claimed. Claim it →

Background

Career
Washington, DC · current
Government experience
Legislative Asst.
Rep. Martha Roby; Legislative Asst., Rep. Lee Terry; Staff Asst./LC, Senator Jeff Sessions
Covered official positions, as disclosed on federal filings

The past 12 months

Clients
19
past 12 months
Filings
33
past 12 months
Agencies contacted
HOUSE OF REPRESENTATIVESSENATEExecutive Office of the President (EOP)Health & Human Services, Dept of (HHS)

Specific issues

Medicaid State-Directed Payments and Intergovernmental Transfers.
Medicare/Medicaid · 2026 Q2
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs.
Health Issues · 2026 Q2
Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.
Pharmacy · 2026 Q2
Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.
Health Issues · 2026 Q2
Issues related to USTR/trade.
Trade (domestic/foreign) · 2026 Q2
Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.
Pharmacy · 2026 Q2

Clients

$██,███ / qtrFree in beta
2026 · 2 filings
$██,███ / qtrFree in beta
2026 · 2 filings
$██,███ / qtrFree in beta
2026 · 2 filings
$██,███ / qtrFree in beta
2026 · 2 filings
$██,███ / qtrFree in beta
$██,███ / qtrFree in beta
2026 · 2 filings
$██,███ / qtrFree in beta
2026 · 2 filings
$██,███ / qtrFree in beta
$██,███ / qtrFree in beta
$██,███ / qtrFree in beta
2026 · 2 filings
$██,███ / qtrFree in beta
$██,███ / qtrFree in beta
2026 · 2 filings
$██,███ / qtrFree in beta
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta

Sources

This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗

Recent filings14
2026 Q2
SAVARA INC.
Q2lda.gov →
2026 Q2
HARMONY BIOSCIENCES
Q2lda.gov →
2026 Q2
ALKERMES, INC.
Q2lda.gov →
2026 Q2
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Q2lda.gov →
2026 Q2
PTC THERAPEUTICS, INC.
Q2lda.gov →
2026 Q2
MEDICAL DEVICE MANUFACTURERS ASSOCIATION
Q2lda.gov →
2026 Q2
NEUROPACE, INC.
Q2lda.gov →
2026 Q2
GLAXOSMITHKLINE LLC
Q2lda.gov →
2026 Q2
ERISA INDUSTRY COMMITTEE (ERIC)
Q2lda.gov →
2026 Q2
NATERA, INC.
Q2lda.gov →
2026 Q2
UNIVERSITY OF LOUISVILLE HEALTH
Q2lda.gov →
2026 Q2
ALNYLAM PHARMACEUTICALS, INC.
Q2lda.gov →
2026 Q2
NATERA, INC.
RRlda.gov →
2026 Q2
UNIVERSITY OF LOUISVILLE HEALTH
RRlda.gov →